Hepcidin demonstrates a biphasic association with anemia in acute Plasmodium falciparum malaria

Climent Casals-Pascual1, Honglei Huang, Samira Lakhal-Littleton

  • 1Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK. ccasals@well.ox.ac.uk

Haematologica
|June 13, 2012
PubMed

Insights

In acute malaria, high hepcidin levels limit iron absorption. Iron supplementation is likely ineffective during acute malaria and for a week post-treatment due to elevated hepcidin.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Immunology

Background:

  • Acute malaria is associated with elevated hepcidin levels, which restrict iron absorption.
  • The precise mechanisms regulating hepcidin secretion during malaria remain unclear.
  • Understanding hepcidin's role is crucial for managing anemia in malaria patients.

Purpose of the Study:

  • To investigate hepcidin concentration and its relationship with cytokines in children with acute falciparum malaria.
  • To determine how hepcidin levels change during and after malaria treatment.
  • To assess the impact of malaria severity and parasite load on hepcidin regulation.

Main Methods:

  • Measured hepcidin concentrations and cytokine levels (IL-10, IL-6) in 100 Kenyan children with acute falciparum malaria.
  • Assessed hepcidin levels at admission, one week, and one month post-treatment.
  • Correlated hepcidin levels with hemoglobin, parasite density, and cytokine concentrations.

Main Results:

  • Hepcidin levels were significantly elevated upon admission and decreased after treatment.
  • A non-linear association was observed between hepcidin and hemoglobin; severe malarial anemia showed very low hepcidin.
  • Parasite density, IL-10, and IL-6 were significantly associated with hepcidin concentration.

Conclusions:

  • Elevated hepcidin during acute malaria promotes iron sequestration, rendering iron administration futile.
  • High hepcidin levels persist for up to a week post-treatment, impairing iron utilization.
  • Iron supplementation policies must consider these findings to optimize anemia management in malaria patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Diversity of Protists II01:27

Diversity of Protists II

Alveolates are a group of organisms recognized by the presence of alveoli, which are cytoplasmic sacs located beneath the cell membrane. While their function remains uncertain, alveoli may help regulate water balance by controlling how much water enters and leaves the cell. In dinoflagellates, these structures may serve as armor plates. There are three major types of alveolates: ciliates, which move using cilia; dinoflagellates, which use flagella for movement; and apicomplexans, which are...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...